The search for a potent DNA vaccine against AIDS: The enhancement of immunogenicity by chemical and genetic adjuvants

Anticancer Research

Volumn 18, Issue 5 D, 1998, Pages 3907-3915

  Sasaki, Shin ^a   Tsuji, Takashi ^a   Asakura, Yusuke ^a   Fukushima, Jun ^a   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Adjuvant; AIDS; Cytokine; DNA vaccine; Immunomodulatory molecules

Indexed keywords

BESTATIN; CD86 ANTIGEN; CYTOKINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LIPOSOME; PHOSPHORYL LIPID A; PLASMID DNA; QS 21;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOKINE RELEASE; DNA SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOID CELL; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; HIV ANTIBODIES; HIV-1; HUMANS; VACCINES, DNA;

EID: 0031775363     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (77)

1. Robinson HL, and Torres CA: DNA vaccines. Seminars Immunol 9: 271-283, 1997.
2. Donnelly JJ, Ulmer JB, Shiver JW, and Liu MA: DNA VACCINES. Ann Rev Immunol 15: 617-648, 1997.
3. Hassett DE, and Whitton JL: DNA immunization. Trend Microbiol 4: 307-312, 1996.
4. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Rafaeli Y, Sato AI, Boyer J, Williams WV, and Weiner DB: Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90: 4156-4160, 1993.
5. Lu S, Santoro JC, Fuller DH, Haynes JR, and Robinson HL: Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 209: 147-154, 1995.
6. Okuda K, Bukawa H, Hamajima K, Kawamoto S, Sekigawa K, Yamada Y, Tanaka S, Ishi N, Aoki I, Nakamura M, Yamamoto H, Cullen BR, and Fukushima J: Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res Hum Retroviruses 11: 933-943, 1995.
7. Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Wiliams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, and Weiner DB: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med 3: 526-532, 1997.
8. Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, and Robinson HL: Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 70: 3978-3991, 1996.
9. Powell MF, and Newman MJ. 1995. Vaccine Design: The subunit and adjuvant approach. In: Pharmaceutical Biotechnology, vol. 6. R. T. Borchardt, ed. Plenum Press, New York.
10. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, and Felgner PL: Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468, 1990.
11. Germain RN: The ins and outs of antigen processing and presentation. Nature 322: 687-689, 1986.
12. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, and Robinson HL: DNA vaccines - protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 90: 11478-11482, 1993.
13. Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, Fukushima J, Wahren B, and Okuda K: Intranasal immunization of a DNA vaccine with interleukin 12 and granulocyte macrophage colony stimulating factor (GM-CSF) expressing plasmids in liposomes induce strong mucosal and cell-mediated immune responses against HIV-1 antigen. J Immunol 159: 3638-3647, 1997.
14. Ban EM, van Ginkel FW, Simecka JW, Kiyono H, Robinson HL, and McGhee JR: Mucosal immunization with DNA encoding influenza hemagglutinin. Vaccine 15: 811-813, 1997.
15. Wang B, Dang K, Agadjanyan MG, Srikantan V, Li F, Ugen KE, Boyer J, Merva M, Williams WV, and Weiner DB: Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine 15: 821-825, 1997.
16. Robinson HL, Hunt LA, and Webster RG: Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11: 957-960, 1993.
17. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiver JW, Montgomery DL, and Liu MA: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749, 1993.
18. Manickan E, Rouse RJ, Yu Z, Wire WS, and Rouse BT: Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. J Immunol 155: 259-265, 1995.
19. Whalen RG: DNA-based immunization and the immune response to the hepatitis B surface antigen. Vet Res 26: 217-220, 1995.
20. Davis HL, Michel ML, and Whalen RG: DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 2: 1847-1851, 1993.
21. Barry MA, Lai WC, and Johnston SA: Protection against mycoplasma infection using expression-library immunization. Nature 377: 632-635, 1995.
22. Bourne N, Stanberry LR, Bernstein DI, and Lew D: DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 173: 800-807, 1996.
23. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, Ulmer JB, and Liu MA: Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nature Med 1: 583-587, 1995.
24. Xiang ZQ, and Ertl HCJ: Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2: 129-135, 1995.
25. Syrengelas AD, Chen TT, and Levy R: DNA immunization induces protective immunity against B-cell lymphoma. Nature Med 2: 1038-1041, 1996.
26. Sedegah M, Hedstrom R, Hobart P, and Hoffman SL: Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 91: 9866-9870, 1994.
27. Cease KB, and Berzofsky JA: Toward a vaccine for AIDS: The emergence of immunobiology-based vaccine development. Ann Rev Immunol 12: 923-989, 1994.
28. Ada GL, and McElrath MJ: HIV type 1 vaccine-induced cytotoxic T cell responses: Potential role in vaccine efficacy. AIDS Res Hum Retroviruses 13: 205-210, 1997.
29. Inami S, Taniguchi N, Ishibashi K, Nagao T, Aoki I, Ishii N, and Okuda K: Serum antibody directed against synthetic peptides derived from HIV-1 protein sequence obtained from 26 Japanese HIV-1-infected individuals. AIDS 5: 1140-1141, 1991.
30. Ubolyam S, Ruxrungtham K, Sirivichayakul S, Okuda K, and Phanuphak P: Evidence of three HIV-1 subtypes in subgroups of individuals in Thailand. Lancet 344: 485-486, 1994.
31. Okuda K, Bukawa H, Kawamoto S, Imai M, Saito T, Phanuphak P, and Hamajima K: A serologic analysis and the amino acid sequence of the V3 region of human immunodeficiency virus from carriers in Bangkok. J Infect Dis 169: 227-228, 1994.
32. Xin KQ, Ma XH, Crandall KA, Bukawa H, Ishigatsubo Y, Kawamoto S, and Okuda K: Dual infection with HIV-1 Thai subtype B and E. Lancet 346: 1372-1373, 1995.
33. Xin KQ, Shapshak P, Kawamoto S, Nagano I, McCoy CB, and Okuda K: Highly divergent env sequences of HIV-1 B subtype with two novel V3 loop motifs detected in an AIDS patient in Miami, Florida. AIDS Res Hum Retroviruses 11: 1139-1141, 1995.
34. Mohri H, Asakura Y, Fukushima J, Kawamoto S, Okubo T, and Okuda K: Synthetic peptide from the V3 loop consensus motif with a potent anti-HIV activity inhibits ristocetin-mediated vWF-GPIb interaction. Peptides 18: 1289-1293, 1997.
35. Okuda K, Kaneko T, Yamakawa T, Tanaka S, Shigematsu T, Yamamoto A, Hamajima K, Nakajima K, Kawamoto S, and Phanuphak P: Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection. J Mol Recognit 6: 101-109, 1993.
36. Hamajima K, Bukawa H, Fukushima J, Kawamoto S, Kaneko T, Sekigawa K, Tanaka S, Tsukuda M, and Okuda K: A macromolecular multicomponent peptide vaccine prepared using the glutaraldehyde conjugation method with strong immunogenicity for HIV-1. Clin Immunol Immunopathol 77: 374-379, 1995.
37. Bukawa H, Sekigawa K, Hamajima K, Fukushima J, Yamada Y, Kiyono H, and Okuda K: Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nature Med 1: 681-685, 1995.
38. Okuda K, Xin K-Q, Tsuji T, Bukawa H, Tanaka S-I, Koff WC, Tani K, Okuda K, Honma K, Kawamoto S, Hamajima K, and Fukushima J: DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity. Vaccine 15: 1049-1056, 1997.
39. Asakura Y, Hamajima K, Fukushima J, Mohri H, Okubo T, and Okuda K: Induction of HIV-1 nef-specific cytotoxic T lymphocytes by nef-expressing DNA vaccine. Am J Hematol 53: 116-117, 1996.
40. Asakura Y, Hinkula J, Leandersson AC, Fukushima J, Okuda K, and Wahren B: Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand J Immunol 46: 326-330, 1997.
41. Hinkula J, Svanholm C, Schwartz S, Lundholm P, Brytting M, Engstrom G, Benthin R, Glaser H, Sutter G, Kohleisen B, Erfle V, Okuda K, Wigzell H, and Wahren B: Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 71: 5528-5535, 1997.
42. Putkonen P, Thorstensson R, Walther L, Albert J, Akerblom L, Granquist O, Wadell G, Norrby E, and Biberfeld G: Vaccine protection against HIV-2 infection in cynomolgus monkeys. AIDS Res Hum Retroviruses 7: 271-277, 1991.
43. Shafferman A, Jahrling PB, Benveniste RE, Lewis MG, Phipps TJ, Eden MF, Sadoff J, Eddy GA, and Burke DS: Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A 88: 7126-7130, 1991.
44. Girard M, Kieny MP, Pinter A, Barre SF, Nara P, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E et al: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A 88: 542-546, 1991.
45. Malim MH, Hauber J, Fenrick R, and Cullen BR: Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335: 181-183, 1988.
46. Vogel FR: Immunologic adjuvants for modern vaccine formulations. Ann NY Acad Sci 754: 153-160, 1995.
47. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, and Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549, 1995.
48. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, and Raz E: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273: 352-354, 1996.
49. Iwasaki A, Torres CA, Ohashi PS, Robinson HL, and Barber BH: The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 159: 11-14, 1997.
50. Corr M, Lee DJ, Carson DA, and Tighe H: Gene vaccination with naked plasmid DNA: Mechanism of CTL priming. J Exp Med 184: 1555-1560, 1996.
51. Sasaki S, Tsuji T, Hamajima K, Fukushima J, Ishii N, Kaneko T, Xin K-Q, Mohri H, Aoki I, Okubo T, Nishioka K, and Okuda K: Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect Immun 65: 3520-3528, 1997.
52. Tsuji T, Fukushima J, Hamajima K, Ishii N, Aoki I, Xin K-Q, Bukawa H, Ishigatsubo Y, Tani K, Okubo T, Dorf ME, and Okuda K: HIV-1-specific cell-medialed immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine. Immunology 90: 1-6, 1997.
53. Sasaki S, Fukushima J, Arai H, Kusakabe K, Hamajima K, Ishii N, Hirahara F, Okuda K, Kawamoto S, Ruysschaert J-M, Vandenbranden M, Wahren B, and Okuda K: Human immunodeficiency virus type 1 specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine. Eur J Immunol 27: 3121-3129, 1997.
54. Sasaki S, Hamajima K, Fukushima J, Tsuji T, Xin K-Q, Ishii N, Mohri H, and Okuda K: Adjuvant effect of ubenimex on the responses induced by DNA vaccine for human immunodeficiency virus rype-1. Clin Exp Immunol 111: 30-36, 1998.
55. Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, Kawamoto S, Mohri H, Kensil CR, and Okuda K: Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol 72: in press, 1998.
56. Kuklin N, Daheshia M, Karem K, Manickan E, and Rouse BT: Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 71: 3138-3145, 1997.
57. Tsuji T, Hamajima K, Ishii N, Aoki I, Fukushima J, Xin KQ, Kawamoto S, Sasaki S, Matsunaga K, Ishigatsubo Y, Tani K, Okubo T, and Okuda K: Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Eur J Immunol 27: 782-787, 1997.
58. Tsuji T, Hamajima K, Fukushima J, Xin K-Q, Ishii N, Aoki I, Ishigatsubo Y, Tani K, Kawamoto S, Nitta Y, Miyazaki J, Koff WC, Okubo T, and Okuda K: Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 158: 4008-4014, 1997.
59. Iwasaki A, Stiernholm BJN, Chan AK, Berinstein NL, and Barber BH: Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 158: 4591-4601, 1997.
60. Chow Y-H, Huang W-L, Chi W-K, Chu Y-D, and Tao M-H: Improvement of hepatitis B virus DNA vaccine by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 71: 169-178, 1997.
61. Gregoriadis G, Saffie R, and de Souza JB: Liposome-mediated DNA vaccination. FEBS Lett 402: 107-110, 1997.
62. Ishii N, Fukushima J, Kaneko T, Okada E, Tani K, Tanaka S-I, Hamajima K, Xin K-Q, Kawamoto S, Koff W, Nishioka K, Yasuda T, and Okuda K: Cationic liposomes are a strong adjuvant of DNA vaccine for human immunodeficiency virus type-1 (HIV-1). AIDS Res Hum Retroviruses 13: 1421-1428, 1997.
63. Toda S, Ishii N, Okada E, Kusakabe K-I, Arai H, Hamajima K, Gorai I, Nishioka K, and Okuda K: HIV-1 specific cell-mediated immune responses induced by DNA vaccination are enhanced by mannan-coated liposomes and inhibited by anti-interferon (IFN)-g antibody. Immunology 92: 111-117, 1997.
64. Ulrich JT, and Myers KR: Monophosphoiyl lipid A as an adjuvant. Past experiences and new directions. In: Vaccine Design (M. F. Powell, and M. J. Newman, eds.) New York, Plenum Press, 1995, pp. 495-523.
65. Sasaki S, Hamajima K, Fukushima J, Ihata A, N. I, Gorai I, Hirahara H, Mohri H, and Okuda K: Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect Immun 66: 823-826, 1998.
66. Kensil CR, Patel U, Lennick M, and Marciani D: Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146: 431-437, 1991.
67. Kensil CR, Wu JY, and Soltysik S: Structural and immunological characterization of the vaccine adjuvant QS-21. In: Vaccine design: The subunit and adjuvant approach (M. F. Powell, and M. J. Newman, eds.) New york, NY, Plenum Press, 1995, pp. 525-541.
68. Umezawa H, Aoyagi T, Suda H, Hamada M, and Takeuchi T: Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot 29: 97-99, 1976.
69. Mathé G: Bestatin, an aminopeptidase inhibitor with a multipharmacological function. Biomed Pharmacother 45: 49-54, 1991.
70. Zhu N, Liggitt D, Liu Y, and Debs R: Systemic gene expression after intravenous DNA delivery into adult mice. Science 261: 209-211, 1993.
71. Felgner PL, Tsai YJ, Sukhu L, Wheeler CJ, Manthorpe M, Marshall J, and Cheng SH: Improved cationic lipid formulations for in vivo gene therapy. Ann N Y Acad Sci 772: 126-139, 1995.
72. Torres CA, Iwasaki A, Barber BH, and Robinson HL: Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol 158: 4529-4532, 1997.
73. Luo Y, Laning J, Devi S, Mak J, Schall TJ, and Dorf ME: Biologic activities of the murine b-chemokine TCA3. J Immunol 153: 4616-4622, 1994.
74. Schijns VE, Haagmans BL, and Horzinek MC: IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice. J Immunol 155: 2525-2532, 1995.
75. Davis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, and Cheever MA: Granulocytes-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccine. Blood 88: 202-210, 1996.
76. Townsend SE, and Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368-370, 1993.
77. Hohlfeld R, and Engel AG: The immunobiology of muscle. Immunol Today 15: 269-274, 1994.